143 related articles for article (PubMed ID: 36049756)
21. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
22. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Zhang S; Qi Z; Wang Y; Song D; Zhu D
Front Endocrinol (Lausanne); 2023; 14():1203666. PubMed ID: 37465122
[TBL] [Abstract][Full Text] [Related]
23. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
24. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
Liu XY; Zhang N; Chen R; Zhao JG; Yu P
J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
[TBL] [Abstract][Full Text] [Related]
26. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Feng C; Wu M; Chen Z; Yu X; Nie Z; Zhao Y; Bao B
Int Urol Nephrol; 2019 Apr; 51(4):655-669. PubMed ID: 30830656
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Zhuang Y; Song J; Ying M; Li M
Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
[TBL] [Abstract][Full Text] [Related]
28. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
Wang H; Yang J; Chen X; Qiu F; Li J
Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
30. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
31. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
[TBL] [Abstract][Full Text] [Related]
32. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
33. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Liu X; Chen Y; Liu T; Cai L; Yang X; Mou C
Front Endocrinol (Lausanne); 2023; 14():1115321. PubMed ID: 36777342
[TBL] [Abstract][Full Text] [Related]
34. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
Wei W; Liu J; Chen S; Xu X; Guo D; He Y; Huang Z; Wang B; Huang H; Li Q; Chen J; Chen H; Tan N; Liu Y
Front Endocrinol (Lausanne); 2022; 13():850836. PubMed ID: 35330914
[TBL] [Abstract][Full Text] [Related]
35. The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials.
Teo YH; Chia AZQ; Teo YN; Chong EY; Syn NL; Cheong JYA; Ong HT; Wee CF; Ting AZH; Tan JTA; Li TYW; Kong WKF; Lee CH; Chan MY; Wong RCC; Yeo TC; Chai P; Sia CH
J Hypertens; 2022 Dec; 40(12):2353-2372. PubMed ID: 36018229
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
37. Effect of sodium-glucose cotransporter protein-2 inhibitors on left ventricular hypertrophy in patients with type 2 diabetes: A systematic review and meta-analysis.
Wang Y; Zhong Y; Zhang Z; Yang S; Zhang Q; Chu B; Hu X
Front Endocrinol (Lausanne); 2022; 13():1088820. PubMed ID: 36699027
[TBL] [Abstract][Full Text] [Related]
38. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
40. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
Dicembrini I; Tomberli B; Nreu B; Baldereschi GI; Fanelli F; Mannucci E; Monami M
Diabetes Res Clin Pract; 2019 Jul; 153():138-144. PubMed ID: 31150722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]